Published June 23, 2026 · @dailyanalysts · Data as of June 22, 2026 close (Finnhub/Yahoo). AXTI closed $92.44, +9.31% (prev close $84.57; intraday $95.80/$84.41; after-hours ~$92.00). Market cap ~$5.9B on ~63.5M Q2 share count. Beta 1.87. 52-wk range $1.80–$143.16.
AXTI jumped 9.3% to $92.44. Three things hit together:
Here is the part the tape is glossing over: the Casela deal (8-K filed June 17, signed June 11) is only RMB 173M ≈ US$25.4M, for calendar 2027, to Nanjing Casela — a China-domestic customer. Domestic China shipments need no export permit. So the "limits export risk" framing is technically true, but the real message is that AXT's next leg of contracted growth is coming from China-domestic demand, not the US-hyperscaler LTSA the bulls have been promised since April. Structurally positive for permit risk; structurally negative for the "neutral global chokepoint" valuation premium. Casela must prepay 50% within 15 business days and take ≥80% of volume or pay a cancellation fee — so it is a real, cash-backed order, just a small and domestically-concentrated one.
| Metric | Q1 2026 (reported Apr 30) | Q2 2026 guide |
|---|---|---|
| Revenue | $26.9M (+39% YoY, +17% QoQ) | ≥$34M (permit-gated; "significant upside" possible) |
| InP revenue | $13.6M (>50% of sales, first time) | >$17M — company record |
| Non-GAAP gross margin | 29.9% (vs −6.4% a yr ago) | >30% |
| GAAP EPS | −$0.03 (beat −$0.05 cons.) | +$0.05 to +$0.07 — first profit ever |
| InP backlog | >$100M (up from ~$60M) | — |
This is the substance behind the run: a 36-point gross-margin swing in a year, InP crossing half of revenue, and the first profitable quarter in company history guided for Q2. The narrative-to-earnings conversion has started — that is a fact, not hype. Management (CFO Gary Fischer, on the call) was explicit that "the most significant single factor to our growth in Q2 and beyond is the success and timing of getting export permits" — the binary that can erase a quarter with zero operational failure.
AXT plans to scale InP factory output from a historical peak of ~$17M/qtr to $35M/qtr by end-2026 (≈$140M annualized) and $65–70M/qtr by late-2027/early-2028 (≈$280M annualized), funded by the $632.5M April raise (8.56M shares at $64.25). CapEx: $30–40M (2026), ~$100M (2027 adjacent facility), $220–250M (later greenfield).
In the last 6 months: 26 open-market sales, 0 purchases. CEO Morris Young sold ~559,964 shares (~$37.5M); CFO Gary Fischer ~$4.5M; director David Chang ~$2.5M; Jesse Chen ~$6.0M across 14 sales — including sales through June 8–12 at $86–$95. Some of this is mechanical/diversification after a >5,000% run, and the company did just raise authorized shares from 70M to 120M (more dilution headroom). But the signal is hard to spin: at the "first profit ever" inflection, the people who know the order book best are distributing, not accumulating. Institutional flow was a wash-out in Q1 — Davidson Kempner exited 2.73M shares, Point72 and Hood River trimmed hard, while Jane Street (+1.5M) and WT Asset (+1.35M) added. High churn, not conviction accumulation.
FY2025 revenue was $88.3M with a $21M net loss. At ~$92, the ~$5.9B cap is ~46x run-rate (Q2-annualized) sales and ~70x trailing. Even granting full 2027 capacity of ~$280M revenue and a generous (and unproven) 18–20% net margin, that's ~$50M net income — still ~110x 2027 earnings. Zacks tags it Value Score F, forward P/S ~52x vs a 5-yr median of 1.48. The price already embeds flawless execution through 2027 against a rising competitive supply response and binary permit risk.
| Idea | Entry | Target | Invalidation | Timeframe | Conviction |
|---|---|---|---|---|---|
| Buy-the-dip long (preferred) | $70–78 | $108, then $125 | Weekly close <$66 | 1–3 months | HIGH on the dip |
| Momentum continuation | Hold >$84 & break/close >$96 | $115–125 | Daily close <$83 | 1–3 weeks (into Q2) | SPECULATIVE |
| Chase at $92 | — | — | — | — | AVOID / WATCH |
Why not chase: upside to the high target ($125) is ~+35%; base/bear downside to $70–76 is −18% to −22% and the regime tail is worse. At consensus, with a small China-domestic catalyst, insiders selling, and a coming competitive supply build, the asymmetry favors patience. I'd rather own this name 15% lower with the Q2 print confirmed than chase it 9% higher on a $25M deal.
Not investment advice. Opinions are the author's. AXTI is a high-volatility (beta ~1.87), permit-dependent small/mid-cap; position size accordingly.